Quantifying nanoparticle transport in vivo using hyperspectral imaging with a dorsal skinfold window chamber

Journal of Innovative Optical Health Sciences

Volumn 5, Issue 4, 2012, Pages

  Mckee, Trevor D ^a,b   Chen, Juan ^a   Corbin, Ian ^a,d   Zheng, Gang ^a,c   Khokha, Rama ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD STREAMS; CIRCULATION TIME; COMPETITIVE INHIBITION; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DYNAMIC WINDOWS; EPIDERMAL GROWTH FACTOR RECEPTORS; EXTRACELLULAR MATRICES; HIGH-DENSITY LIPOPROTEINS; HYPERSPECTRAL IMAGING; IMAGING METHOD; IMAGING TECHNOLOGY; IN-VIVO; NEAR INFRA RED; NON-INVASIVE IMAGING; REAL TIME MONITORING; TISSUE DEPOSITION; TUMOR SITE; VASCULAR TRANSPORT; WINDOW CHAMBERS;

BLOOD VESSELS; DRUG DELIVERY; INFRARED DEVICES; PEPTIDES; PHARMACOKINETICS; SPECTROSCOPY; TISSUE;

NANOPARTICLES;

EID: 84870887987     PISSN: 17935458     EISSN: 17937205     Source Type: Journal    
DOI: 10.1142/S179354581250023X     Document Type: Article

References (28)

1. R. Ng, N. Better, M. D. Green, "Anticancer agents and cardiotoxicity," Semin. Oncol. 33(1), 2 - 14 (2006).
2. A. Pluen et al., "Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial versus subcutaneous tumors," Proc. Natl. Acad. Sci. USA 98(8), 4628 - 4633 (2001).
3. T. D. McKee et al., "Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector," Cancer Res. 66(5), 2509 - 2513 (2006).
4. H. Maeda et al, "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review," J. Control Release 65(1 - 2), 271 - 284 (2000).
5. F. Yuan et al, "Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size," Cancer Res. 55(17), 3752 - 3756 (1995).
6. S. K. Hobbs et al, "Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment," Proc. Natl. Acad. Sci. USA 95(8), 4607 - 4612 (1998).
7. H. Cabral et al., "Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size," Nat. Nanotechnol. 6(12), 815 - 823 (2011).
8. R. A. Silva et al, "Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes," Proc. Natl. Acad. Sci. USA 105(34), 12, 176 - 12, 181 (2008).
9. W. V. Rodrigueza et al., "Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells," J. Biol. Chem. 274(29), 20, 344 - 20, 350 (1999).
10. M. M. Shahzad et al., "Targeted delivery of small interfering RNA using reconstituted highdensity lipoprotein nanoparticles," Neoplasia 13(4), 309 - 319 (2011).
11. A. Hrzenjak et al, "Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate," Cell Mol. Life Sci. 61(12), 1520 - 1531 (2004).
12. L. K. Mooberry et al, "Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier," J. Drug Target. 18(1), 53 - 58 (2010).
13. P. J. Pussinen et al, "The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake," Biochem. J. 349(2), 559 - 566 (2000).
14. M. K. Bijsterbosch, T. J. Van Berkel, "Lactosylated high density lipoprotein: A potential carrier for the site-specific delivery of drugs to parenchymal liver cells," Mol. Pharmacol. 41(2), 404 - 411 (1992).
15. Z. Zhang et al., "Biomimetic nanocarrier for direct cytosolic drug delivery," Angew. Chem. Int. Ed. Engl. 48(48), 9171 - 9175 (2009).
16. K. K. Ng, J. F. Lovell, G. Zheng, "Lipoproteininspired nanoparticles for cancer theranostics," Acc. Chem. Res. 44(10), 1105 - 1113 (2011).
17. M. Yang et al., "Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide - phospholipid nanoscaffold," Nanomedicine (Lond) 6(4), 631 - 641 (2011).
18. M. Yang et al., "Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles," Small 7(5), 568 - 573 (2011).
19. Lin Q. et al, "Efficient systemic delivery of siRNA by using HDL-mimicking peptide lipid nanoparticles," Nanomedicine (Lond) accepted (2012).
20. R. I. Corbin et al, "Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers," J. Biomed. Nanotechnol. 3, 1 - 10 (2007).
21. Z. Zhang et al., "HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting," Small 6(3), 430 - 437 (2010).
22. H. Jin et al, "Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging," Cancer Nano 1, 71 - 78 (2010).
23. W. Chen et al., "RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe," FASEB J. 24(6), 1689 - 1699 (2010).
24. P. Thevenaz, U. E. Ruttimann, M. Unser, "A pyramid approach to subpixel registration based on intensity," IEEE Trans. Image Process 7(1), 27 - 41 (1998).
25. S. D. Molyneux et al., "Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice," J. Clin. Invest. 120(9), 3310 - 3325 (2010).
26. J. Y. Perentes et al, "In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts," Nat. Methods 6(2), 143 - 145 (2009).
27. S. Eisenberg, H. G. Windmueller, R. I. Levy, "Metabolic fate of rat and human lipoprotein apoproteins in the rat," J. Lipid. Res. 14(4), 446 - 458 (1973).
28. Z. Li et al, "Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics," FASEB J. 19(14), 1978 - 1985 (2005).